{"doi":"10.7150/thno.38882","title":"Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer","abstract":"Auger radiopharmaceutical therapy is a promising strategy for micrometastatic disease given high linear energy transfer and short range in tissues, potentially limiting normal tissue toxicities. We previously demonstrated anti-tumor efficacy of a small-molecule Auger electron emitter targeting the prostate-specific membrane antigen (PSMA), 2-[3-[1-carboxy-5-(4-[ 125 I]iodo-benzoylamino)pentyl]-ureido]-pentanedioic acid), or 125 I-DCIBzL, in a mouse xenograft model. Here, we investigated the therapeutic efficacy, long-term toxicity, and biodistribution of 125 I-DCIBzL in a micrometastatic model of prostate cancer (PC). Methods: To test the therapeutic efficacy of 125 I-DCIBzL in micrometastatic PC, we used a murine model of human metastatic PC in which PSMA+ PC3-ML cells expressing firefly luciferase were injected intravenously in NSG mice to form micrometastatic deposits. One week later, 0, 0.37, 1.85, 3.7, 18.5, 37, or 111 MBq of 125 I-DCIBzL was administered (intravenously). Metastatic tumor burden was assessed using bioluminescence imaging (BLI). Long-term toxicity was evaluated via serial weights and urinalysis of non-tumor-bearing mice over a 12-month period, as well as final necropsy.","journal":"Theranostics","year":2020,"id":94097,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":38,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.962,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":420232,"name":"Il Minn","orcid":"0000-0002-7822-662X","position":1,"is_corresponding":false},{"id":338671,"name":"Robert F. Hobbs","orcid":"0000-0002-1328-7114","position":2,"is_corresponding":false},{"id":17704,"name":"Ying Chen","orcid":"0000-0001-8306-8083","position":3,"is_corresponding":false},{"id":469245,"name":"Anders Josefsson","orcid":"0000-0002-0800-2305","position":4,"is_corresponding":false},{"id":469246,"name":"Mary Brummet","orcid":"0000-0001-9648-6153","position":5,"is_corresponding":false},{"id":74819,"name":"Sangeeta Ray Banerjee","orcid":"0000-0003-3785-7385","position":6,"is_corresponding":false},{"id":297889,"name":"Cory Brayton","orcid":"0000-0002-6666-6548","position":7,"is_corresponding":false},{"id":470476,"name":"Ronnie C. Mease","orcid":null,"position":8,"is_corresponding":false},{"id":7932,"name":"Martin G. Pomper","orcid":"0000-0001-6753-3010","position":9,"is_corresponding":false},{"id":469247,"name":"Ana P. Kiess","orcid":"0000-0001-6928-3852","position":10,"is_corresponding":false},{"id":469244,"name":"Colette J. Shen","orcid":"0000-0002-3855-7360","position":0,"is_corresponding":true}],"reference_count":45,"raw_metadata":null,"created_at":"2026-07-18T22:32:04.778261Z","pmid":"32194842","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}